| Literature DB >> 36109685 |
Sean K Simmons1,2, Gila Lithwick-Yanai3, Xian Adiconis1,2, Florian Oberstrass3, Nika Iremadze3, Kathryn Geiger-Schuller1,4, Pratiksha I Thakore1,4, Chris J Frangieh1,5, Omer Barad3, Gilad Almogy3, Orit Rozenblatt-Rosen1,4, Aviv Regev1,6,4, Doron Lipson3, Joshua Z Levin7,8.
Abstract
Here we introduce a mostly natural sequencing-by-synthesis (mnSBS) method for single-cell RNA sequencing (scRNA-seq), adapted to the Ultima genomics platform, and systematically benchmark it against current scRNA-seq technology. mnSBS uses mostly natural, unmodified nucleotides and only a low fraction of fluorescently labeled nucleotides, which allows for high polymerase processivity and lower costs. We demonstrate successful application in four scRNA-seq case studies of different technical and biological types, including 5' and 3' scRNA-seq, human peripheral blood mononuclear cells from a single individual and in multiplex, as well as Perturb-Seq. Benchmarking shows that results from mnSBS-based scRNA-seq are very similar to those using Illumina sequencing, with minor differences in results related to the position of reads relative to annotated gene boundaries, owing to single-end reads of Ultima being closer to gene ends than reads from Illumina. The method is thus compatible with state-of-the-art scRNA-seq libraries independent of the sequencing technology. We expect mnSBS to be of particular utility for cost-effective large-scale scRNA-seq projects.Entities:
Year: 2022 PMID: 36109685 DOI: 10.1038/s41587-022-01452-6
Source DB: PubMed Journal: Nat Biotechnol ISSN: 1087-0156 Impact factor: 68.164